Gadobenate dimeglumine (MultiHance) for magnetic resonance angiography: review of the literature

Abstract

Although limited in number, reports describing the use of Gd-BOPTA for 3D CE-MRA reveal that this agent is safe, well tolerated and effective for CE-MRA at doses up to 0.3 mmol/kg bodyweight. The use of Gd-BOPTA leads to additional diagnostically relevant information comparable to that attainable with conventional DSA and superior to that on non-enhanced MRA in most arterial territories. In studies in which Gd-BOPTA is compared at equal dose with other gadolinium-based MR contrast agents, Gd-BOPTA has consistently shown significantly better quantitative and qualitative performance. Thus, Gd-BOPTA can be considered to have a very favorable risk/benefit ratio for MRA. In summary, it is likely the documented superiority of Gd-BOPTA for MR angiography will lead to its broad usage for this indication wherever the agent becomes available.